Feb. 06, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings ... cash balance following its recent capital raise, steady progress in the initiation of its Phase 1 clinical trial of CER-1236 ...

Jan. 13, 2025 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq ... “In 2025, we expect important progress across our inhibitor and degrader programs. Our highly selective SMARCA2 ...

GOMEKLI is the first and only medicine approved for both adults and children with NF1-PN –– Approval based on positive data ...

Overall, Gain remains committed to advancing research against Parkinson's, highlighting the potential of GT-02287 to deliver meaningful progress in treatment options. Gain Therapeutics is ...

Feb. 06, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings ... update highlighting its improved cash balance following its recent capital raise, steady progress in the initiation of its Phase 1 ...

Viking Therapeutics showcased significant clinical progress across its pipeline in 2024, with VK2735 emerging as a key driver for future growth. The company is well-positioned for Phase 3 trials ...

Both companies could beat the market again in 2025 as their lead candidates make more progress. Viking Therapeutics got the market's attention with robust phase 2 results for VK2735, a potential ...